The effect of dopaminergic blockade on thyrotrophin response to thyrotrophin-releasing hormone and somatostatin.
Using a large number of animals we have been able to demonstrate that somatostatin administration (20 micrograms/100 g bw) significantly reduces both basal serum thyrotrophin (TSH) levels and the response to thyrotrophin-releasing hormone (TRH) in the normal rat. Pretreatment with the dopaminergic antagonist domperidone resulted in increased TSH levels, increased response to TRH but no modification in the response to somatostatin.
D000818:Animals; D004294:Domperidone / Q000494:pharmacology; D004357:Drug Synergism; D008297:Male; D051381:Rats; D011919:Rats, Inbred Strains; D011954:Receptors, Dopamine / Q000187:drug effects*; D013004:Somatostatin / Q000008:administration & dosage / Q000494:pharmacology*; D013972:Thyrotropin / Q000097:blood*; D013973:Thyrotropin-Releasing Hormone / Q000494:pharmacology*
D011954:Receptors, Dopamine; D013004:Somatostatin; D004294:Domperidone; D013973:Thyrotropin-Releasing Hormone; D013972:Thyrotropin